The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be ...

Columnist Candace Semien praises the community's ability to survive and thrive without guilt while living with lupus.

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...

ALM-223 is under development for the treatment of systemic lupus erythematosus (SLE) and atopic dermatitis (AD). It is administered through subcutaneous route in the form of liquid. It is a fusion ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

Atherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in ...

Discover a study where results suggest that patients with cutaneous lupus erythematosus may benefit from increased vigilance ...